Thrombophilia, which severely impacts on morbidity and mortality of polycythaemia vera and essential thrombocythaemia, is variably characterized by microcirculatory disturbances, arterial and venous thromboses that often precede disease recognition. Thus, the search for Janus Kinase 2 mutation, the molecular marker of myeloproliferative neoplasms, is becoming increasingly common particularly in patients with vein thromboses at atypical sites. Although the pathogenesis of thrombophilia is still elusive, platelet and leukocyte abnormalities seem particularly critical and likely account for the antithrombotic efficacy of aspirin and hydroxyurea.
Introduction
The clinical course of myeloproliferative neoplasms (MPNs), and particularly of polycythaemia vera (PV) and essential thrombocythaemia (ET), is characterized by a thrombophilic state that manifests with microcirculatory disturbances and arterial and venous thromboses. The development of an effective and safe strategy for preventing these vascular complications is the main challenge in the treatment and management of patients with these diseases. These subjects also have coagulation laboratory abnormalities, and the relationship between these haemostatic changes and clinical manifestations of thrombophilia was extensively investigated over the last three decades. Some clinical features such as the microcirculatory disturbances and the mucocutanous bleedings, which may paradoxically co-exist in some patients, initially oriented scientific efforts towards functional and biochemical platelet studies and led to the characterization of several platelet abnormalities. More recently, a number of studies also drew attention towards leukocytosis as a novel marker of vascular risk.
1,2 Furthermore, leukocyte activation and platelet-leukocyte interaction were proposed as potential determinants of the haemostatic imbalance. 3, 4 Important research objectives, however, are still unmet. In fact, mechanisms underlying the MPN thrombotic diathesis are still largely elusive and laboratory studies have provided data that were often conflicting or difficult to interpret as to their clinical or pathogenetic significance. Some knowledge gap was filled over the last few years as largescale clinical studies added new information on clinical epidemiology as well as on risk/benefit ratio of some treatment strategies in PV and ET. 5, 6 In addition, the identification of the Janus Kinase 2 (JAK2) mutation 7, 8 provided a new tool for characterizing MPN patients and for interpreting the heterogeneity of laboratory data. Thus, to fully exploit the potential of these new clues, in this paper, the results of laboratory findings are discussed together with some new clinical data gathered in PV and ET. Indeed, haemostatic abnormalities have been most extensively investigated in PV and ET, whereas data from other MPNs are scanty and will not be discussed here.
Clinical manifestations of vascular events in MPN patients

Microcirculatory disturbances
Microcirculatory disturbances are the most typical thrombotic manifestations in PV and ET patients, and are responsible for a wide range of clinical symptoms arising from the formation of platelet thrombi in the end-arterial circulation of the peripheral, cerebral, coronary, skin and abdominal vessels. 9 The most common clinical manifestations are erythromelalgia, visual and hearing symptoms, Raynaud phenomenon and untreatable headache. Although typically affecting ET and PV subjects with thrombocytosis, erythromelalgic attacks may also manifest in subjects with some types of myelodysplastic syndrome or with other non-haematological disorders. 10, 11 Erythromelalgia, however, never occurs in secondary thrombocytosis, thus confirming that qualitative platelet abnormalities have a major function in the pathogenesis of this phenomenon. 12 Other clinical manifestations of microcirculatory disturbances are transient neurological and ocular ischaemias, which prevalently cause poorly localized symptoms such as transient unsteadiness and scintillating scotomata. Focal symptoms such as dysarthria, transient monocular blindness or transient mono-or hemiparesis are less common. 13 Visual dysfunction may also manifest as transient diplopia and sudden reversible attacks of blurred vision.
Arterial thromboses
The incidence of thrombosis in MPN subjects has been recently reassessed in large-scale studies. As shown in Table 1 , arterial thrombotic manifestations are very common at diagnosis both in PV and ET patients with an apparent reduction of the thrombotic risk during follow-up.
Thrombotic occlusions of large arteries most commonly involve cerebral or coronary vessels. Ischaemic stroke, once the common cause of death in untreated PV subjects, still constitutes 30-40% of all thrombotic events in PV patients. 16 Acute coronary syndromes are rarer, particularly during followup of well-treated PV subjects, but there are several reports of myocardial infarction in PV subjects with normal coronary arteries. 24 Acute vascular occlusions in other districts are not uncommon both in PV and ET patients. 25 The high incidence of heart valvular lesions in MPN raises the possibility that a significant proportion of these accidents may be related to emboli of cardiac origin. 26 The large database collected by the European Collaboration of Low dose Aspirin in PV (ECLAP) allowed to study the incidence of the various events during the course of the disease. 16 This analysis confirmed the high prevalence of stroke at diagnosis and the tendency of thrombophilia to manifest 5-6 years before diagnosis, as also shown by an earlier retrospective study.
14 In these patients, as in ET subjects, arterial thromboses were confirmed to involve, in descending frequency, cerebral, coronary and peripheral arteries. Transient ischaemic attacks are as common as stroke and their incidence seems relatively unaffected by a treatment that markedly reduces the risk of major stroke (Figure 1 ). On the other hand, relatively little information is available on the type of ischaemic stroke more prevalent in these patients.
Venous thromboses
Venous thrombophilia of PV and ET patients usually manifests with an increased incidence of deep venous thromboses of lower limbs, which may cause pulmonary embolism. Superficial phlebitis of the legs is also common, and venous thromboses at unusual sites are not as rare as in the general population ( Figure 1 ). In PV, venous thromboses are relatively common and constitute approximately one-third of the total events. 16 Thromboses of cerebral sinuses and of splanchnic (portal and hepatic) veins have been repeatedly reported in relatively young female patients. 27, 28 Although the relative prevalence of all the other thrombotic complications does not significantly change during the course of the disease, splanchnic vein thromboses are often an early complication and often manifest before diagnosis (Figure 1) . The prevalence of a latent MPN in subjects with hepatic vein thrombosis or with extra hepatic portal vein thrombosis has been estimated to range between 40 and 60% of cases. 29, 30 Thus, all subjects manifesting with a splanchnic vein thrombosis should be investigated for an occult MPN and, in this view, the search for the JAK2 mutation (see below) is mandatory. 31, 32 Proposed causes for the occurrence of splanchnic thromboses in these patients include increased portal blood flow, congestive splenomegaly and hepatic extramedullary haematopoiesis.
Pathogenetic mechanisms of thrombophilia in PV and ET
Erythrocytosis and red cell abnormalities
In PV, the prothrombotic effect of an elevated haematocrit is clearly demonstrated by the observation that progressively higher haematocrit values are associated with a progressive increase in the thrombotic risk that apparently parallels blood viscosity. 33 In untreated PV subjects, most thrombotic accidents Thrombosis in myeloproliferative disorders R Landolfi et al 2021 occur in the cerebral circulation particularly sensitive to blood hyperviscosity. 34 The latter can increase the thrombotic risk by multiple mechanisms. Under the low-shear conditions of venous circulation, a high haematocrit has a more important effect on blood viscosity and may cause a major disturbance to blood flow. At high shear rates, the axial migration of red blood cells (RBCs) attenuates the flow disturbance but the rise in red cell mass displaces the platelets towards the vessel wall, thus facilitating shear-induced platelet activation and further enhancing the increased platelet-platelet interactions secondary to thrombocytosis. 35, 36 A proper management of blood hyperviscosity is essential but does not abolish the in vivo platelet activation and the increased thrombotic risk in PV subjects. 37 Essential thrombocythaemia subjects, in spite of normal haematocrit values, have a thrombotic diathesis similar to that of polycythaemic subjects. 38 In these two MPNs, there are also RBC abnormalities that include biochemical changes in the cell membrane and content. 39 These changes may independently impair blood flow also through the formation of RBC aggregates that have the potential to directly block blood flow in small vessels, thus contributing to cause ischaemia and infarct, especially in the cerebral blood flow.
SPOTLIGHT
Furthermore, RBC aggregation facilitates the platelet and leukocyte interaction with the vessel wall. 40, 41 Recently, a JAK2-dependent phosphorylation of Lutheran blood group was demonstrated in polycythaemic RBC and found responsible for an enhanced interaction with endothelial laminin a5 chain. 42 This phenomenon is likely to have a function in the pathogenesis of microcirculatory disturbances and, more generally, in the thrombotic diathesis of PV subjects.
Thrombocytosis
Thrombocytosis can contribute to the vascular events of ET or PV, as suggested by the evidence that platelet count reduction lowers the risk of microcirculatory disturbances. [9] [10] [11] 21 The antithrombotic efficacy of chemotherapy in high-risk ET subjects has been clearly demonstrated. 43 However, it may be partially related to an effect on leukocyte count and, possibly, on platelet and leukocyte activation.
Marked thrombocytosis can favour haemorrhagic rather than thrombotic manifestations in ET patients. 44 This paradox is attributed to the possible occurrence, in patients with thrombocytosis, of an acquired von Willebrand syndrome, due to an increased clearance of the large von Willebrand factor multimers from plasma. 45 
Platelet functional abnormalities
Owing to the particular features of a thrombohaemorrhagic diathesis in MPN, most experimental in vitro studies have attempted to demonstrate and characterize possible platelet defects. These efforts have led to the identification of a large number of morphological, functional and biochemical abnormalities whose clinical significance remains, however, elusive. 46, 47 Most functional studies on MPN platelets have been performed by measuring in vitro platelet aggregation in response to various stimuli. 48 In spite of the intrinsic limitation of the technique, aggregation measurements have provided some interesting findings such as the phenomenon of spontaneous aggregation 49 and the reduced platelet response to some aggregating agents such as adenosine diphosphate collagen and epinephrine. 46 In PV and ET platelets, multiple abnormalities of membrane glycoproteins (Gps) and receptors have been reported. Other observed abnormalities involve a reduced expression or function of Gp Ib-and Gp IIb-IIIa-associated receptors and an increased expression of Gp IV. 50, 51 In MPN patients, bleeding time measurements by the Ivy method have been performed to identify subjects with impaired platelet function and increased haemorrhagic risk from either surgical procedures or antiplatelet agent administration. Although not having the limitations of in vitro studies, the clinical utility of the bleeding time in PV and ET subjects has been limited. 52 An enhanced in vivo platelet activation in MPN subjects that was initially suggested on the basis of increased plasma levels of b-thromboglobulin and platelet factor 4 has been confirmed by measuring platelet activation products in the urine. Thus, the excretion of the two major thromboxane (Tx)A2 metabolites, 11-dehydro-TxB2 and 2,3-dinor-TxB2, was measured in PV and ET subjects to estimate the rate of TxA2 biosynthesis in vivo. Both PV and ET subjects were found to have an increased excretion of Tx metabolites largely suppressible by low-dose aspirin and thus related to enhanced platelet production in response to physiological stimuli. 37, 51 On this basis, high Tx metabolite excretion reflects in vivo TX-mediated platelet activation and constituted the biological background for testing the benefit/risk ratio of low-dose aspirin in the ECLAP trial.
Leukocytes
The increase in white blood cell count is a risk factor for thrombosis in patients with PV and ET. 1, 2, 20, 23, 53 However, also qualitative abnormalities of leukocytes, particularly polymorphonuclear leukocytes (PMNs), the most abundant proportion of white blood cell, can occur in these diseases and contribute to the activation of the haemostatic system. In fact, it has been demonstrated that PMNs of PV and ET display phenotypical changes compatible with an 'in vivo' activation status. 3 This activation can affect the haemostatic system by multiple mechanisms (Figure 2) . Indeed, patients with PV or ET have a significantly increased expression of the membrane b2 integrin CD11b and leukocyte alkaline phosphatase, and a significant increase in the cellular content of elastase. 3 These findings, together with the finding of elevated plasma concentrations of elastase and myeloperoxidase, demonstrate an ongoing in vivo PMN activation. Furthermore, the correlation in the same subjects of PMN abnormalities with an increase in the plasma levels of markers of clotting activation (that is, thrombinantithrombin complex, prothrombin fragment 1 þ 2 and D-dimer) and endothelium perturbance (that is, thrombomodulin and von Willebrand factor) supports the hypothesis of an involvement of PMN in the pathogenesis of the hypercoagulable state of patients with ET and PV. Hyperexpression of PMN membrane adhesive molecules (integrins and selectins) increases the adhesion of PMN to endothelial cells and platelets. The cell-cell interaction stimulates the expression of prothrombotic features by endothelial cell and platelet and induces the release from activated PMN of reactive oxygen species and intragranule proteinases, including elastase and cathepsin G. 54, 55 All these products are able to affect a number of haemostatic functions (Figure 2) .
The interaction of PMN with platelets is coordinated by an adhesion cascade of events in which platelet P-selectin (CD62P) binds to PSGL-1 on PMN (Figure 2 ).
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The interplay between activated PMN and activated platelets generates PMN/platelet-mixed aggregates, which are a sensitive marker for platelet activation, and are increased in several pathological conditions associated with a propensity to thrombosis. 58, 59 Different studies describing increased levels of such aggregates in ET and PV have largely attributed this phenomenon to platelet activation. However, PMNs from these patients also express high levels of the b2 integrin CD11b, which is a prominent site for platelet attachment. In a study by Falanga et al., 4 circulating PMN/platelet aggregates were measured simultaneously to the levels of activated PMN and activated platelets. The results of this study suggested a function for activated PMN in the formation of high percentage of circulating mixed aggregates in ET and PV. This interpretation was further supported by the evidence that, in the whole blood samples from the same subjects, the 'in vitro' induced PMN activation (without platelet activation) resulted in a significant increase of PMN-platelet aggregate formation. It is worth noting that in ET patients receiving aspirin, the increment in CD11b and PMN/platelet aggregates was significantly lower compared with non-aspirin-treated ET subjects.
Predictors of venous and arterial thrombosis
Age and thrombotic history in PV and ET Age, which is a well-recognized risk factor for thrombosis, 60 is a major determinant of thrombotic risk also in PV and ET. In fact, all epidemiological studies have reported that the incidence rate of arterial and venous thrombosis increases with age. 2, 16, 20, 23, 53, 61 Also, a previous thrombotic event has been consistently proven to be an independent predictive factor for recurrent thrombosis with an interaction with age that may be more than additive. The previous thrombotic event also predicts the type of recurrence as the latter generally occurs in the same district of the first vascular event in both PV 2, 16 and ET. 62 The thrombotic risk reported for different various age groups and history of thrombosis are summarized in Table 2 .
Cardiovascular risk factors and disease-related parameters
The contribution of well-established risk factors of cardiovascular disease (hypertension, smoking, hypercholesterolaemia and diabetes mellitus) has been assessed in multiple studies with some conflicting results, possibly deriving from the limited size of the studies and from the relatively low number of patients having the specific risk factors. One large retrospective study in ET patients demonstrated the function of hypercholesterolaemia, whereas another study showed the independent association of vascular risk with smoking. Abbreviations: ET, essential thrombocythaemia; NA, not available; no., number; pts, patients; PV, polycythaemia vera.
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In PV, the function of 'classic' cardiovascular risk factors (that is, hypertension, diabetes, smoking and hypercholesterolaemia) was recently investigated in the ECLAP observational study. 2 On multivariate analysis, hypertension was associated with no significant increase of the thrombotic risk, whereas smoking was associated with a significant risk of arterial thrombotic events (hazards ratio (HR) 1.90; 95% confidence interval (CI) 1.15-3.14; P ¼ 0.0120). A similar finding has been reported also in ET. 20 Among the haematological values, leukocyte count is the only parameter found to be associated with the vascular risk in both ET and PV patients. 2, 20, 23, 53 High leukocyte count was associated with thrombosis (X15 Â 10 9 and 48.7 Â 10 9 per l, respectively) in two recent studies in ET in which neither thrombocytosis nor the presence of JAK2 mutation (discussed below) was identified as an additional independent risk factor. Moreover, Tefferi et al. 65 reported in a cohort of 605 patients with ET an independent association between leukocytosis and arterial and venous thrombosis. 64, 65 In PV, the function of leukocytes on vascular risk was investigated in the ECLAP study in which the risk of arterial thrombosis, and particularly of myocardial infarction, was increased in patients with white blood cell count higher than 410 Â 10 9 per l. This increase became statistically significant when white blood cell count was higher than 415 Â 10 9 per l (HR 1.71; 95% CI 1.10-2.65; P ¼ 0.0171). 2 Within the limitations of the relatively wide CIs, the impact of leukocytosis on vascular risk could be compared with that of age and thrombotic history.
Genetic and acquired thrombophilia
Hereditary thrombophilic states such as the congenital deficiencies of natural anticoagulants (antithrombin, protein C and protein S) and genetic mutations (factor V Leiden and prothrombin G20210A) are known to have an important function in the pathogenesis of venous thromboses. In addition, elevated homocysteine levels and the presence of antiphospholipid antibodies may influence the risk for both venous and arterial thromboses. The high prevalence of these conditions in the general population allows predicting that these thrombophilic states may be present in a significant number of PV and ET patients and possibly have a function in amplifying the thrombotic risk. However, the studies that have explored the potential contribution of these conditions to the thrombotic risk provided only limited information. In ET patients, two studies of limited sample size failed to demonstrate a significant difference in the prevalence of factor V Leiden, prothrombin G20210A and MTHFR (methylene-tetrahydrofolare reductase) mutations in subjects with and without thrombotic complications. 66, 67 On the other hand, a large retrospective study involving PV and ET subjects demonstrated that factor V Leiden was significantly more prevalent in patients with a history of venous thrombosis than in subjects with no such history (16 versus 3%). 68 Several studies have demonstrated elevated homocysteine levels among patients with MPN. 69, 70 Many MPN patients develop hyperhomocysteinaemia during the course of the disease, 71 and this has been attributed to vitamin folic acid deficiency. 72 Hyperhomocysteinaemia is likely to increase the thrombotic risk of MPN patients. Kornblihtt et al. 73 evaluated the prevalence and clinical significance of most thrombophilic conditions in 60 ET patients. At least one thrombophilic condition was detected in one-third of patients but there was no difference in the prevalence of a thrombophilic state in ET patients with and without thrombosis. Also, antiphospholipid antibodies were not associated with thrombosis in a recent study 74 but, also in this case, large prospective studies are needed to clarify the prognostic relevance of any inherited or acquired cause of thrombophilia in these diseases.
Current therapeutical management of thrombosis in PV and ET patients
Prevention of thrombosis
The antithrombotic strategies in PV and ET patients are currently tailored on the basis of the vascular risk that can range from less than 1.5% up to more than 6% per annum. A simplified method to assess this risk and the recommendations for the use of available drugs have been recently reported elsewhere. 75 An appropriate treatment of blood hyperviscosity in PV patients is essential and can be performed with phlebotomies in patients with low thrombotic risk whereas in subjects at increased thrombotic risk, hydroxyurea (HU) is the treatment of choice. The high antithrombotic efficacy of HU has been recently shown also in ET. 6 The PT1 trial randomized 809 ET patients to be treated with anagrelide or HU in addition to lowdose aspirin. In spite of comparable control of platelet count in the two arms, the efficacy and safety of HU plus aspirin were significantly higher than those of anagrelide plus aspirin because of a reduced number of both thromboses and bleedings in this group. The high antithrombotic efficacy of HU can be attributed to its effect on leukocyte count and, possibly, on leukocyte activation, 76 whereas the increased bleeding risk of anagrelide could be tentatively attributed to the weak antiaggregating effect of this agent.
The use of aspirin in MPN patients has been long debated since a small-size clinical using high aspirin doses raised the issue of a high-risk of gastrointestinal bleeding from aspirin in this setting. On the other hand, several other findings, including the increased in vivo Tx biosynthesis existing in PV and ET subjects and the selective aspirin efficacy in microcirculatory disturbances, provided a biological rationale for its use.
In a number of clinical trials recruiting both apparently healthy low-risk persons and high-risk patients, aspirin has been shown to reduce the risk of a vascular event by approximately one-quarter, this resulting from one-third reduction in non-fatal myocardial infarction, one-quarter reduction in non-fatal stroke and one-sixth reduction in death from a vascular or unknown cause. 77, 78 These effects could be obtained with aspirin doses (80-160 mg daily) considerably lower than those originally tested in PV.
Thus, the effectiveness of 100 mg per day aspirin in reducing the incidence of vascular events was investigated in the ECLAP study that randomized 518 PV patients to be treated with lowdose aspirin or placebo. 5 After a median follow-up of 2.7 years, there was a significant reduction of combined risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and major venous thrombosis (RR 0.40, 95% CI: 0.18-0.91) without a significant increase of the bleeding risk. 5 As this favourable benefit/risk ratio was observed in a relatively low-risk PV population (that is, subjects with no thrombotic history), it seems reasonable to recommend aspirin use to all PV subjects having no contraindication to this treatment. Now some aspirin debate exists in ET as, in this disease, the efficacy and safety of low-dose aspirin has been evaluated only in small-size studies. 79 Particularly controversial is the use of aspirin in low-risk young ET subjects whose vascular risk is likely to be lower than the threshold level usually recommended for considering aspirin use in the general SPOTLIGHT Thrombosis in myeloproliferative disorders R Landolfi et al population (1.5% per annum) and whose bleeding risk is currently unknown. For patients who are intolerant to aspirin, ticlopidine and clopidogrel can be considered as alternative antiplatelet agents although there are no clinical studies on the use of these agents in this specific setting.
Prevention of thrombosis during surgical procedures
A retrospective analysis was performed to estimate the frequency of post-surgical thrombosis in PV and ET patients. This analysis involved 105 PV and 150 ET subjects and recorded clinical outcomes within 3 months from surgery. The study reported 12 arterial and venous thromboses and five deaths (two acute myocardial infarction, two ischaemic strokes and one multiorgan failure) in 13% of patients. The treatment with heparin or antiplatelet drugs had no apparent effect on adverse outcomes, although there was a trend for heparin efficacy in the prevention of venous thromboembolism (VTE). Despite therapy, a significant proportion of surgeries (5% of 155 major surgeries and 2.5% of 156 minor surgeries) were complicated by an episode of symptomatic deep venous thrombosis. 80 Moreover, the overall incidence of bleeding complications was 10.5% (30 episodes in 284 surgeries). There was a clear trend for an increased bleeding risk in those subjects receiving antithrombotic prophylaxis versus no prophylaxis (heparin versus no prophylaxis: HR 1.7; 95% CI 0.7-7.7; antiplatelet therapy versus no prophylaxis: HR 2.4; 95% CI 0.8-7.7). The haemorrhagic risk was largely limited to the postsurgical period with a higher incidence in the first 15 days. 80 Despite its limitations, this study demonstrated an increased risk of both thrombotic and bleeding events in MPN patients and a postsurgical incidence of deep venous thrombosis approximately fivefold higher than in the general population, comparable with that of neoplastic patients receiving no prophylaxis. The high thrombohaemorrhagic risk associated with surgical procedures is likely to be reduced by an optimal control of haematological parameters. Thus, whenever possible, surgery should be differed until such a control is achieved.
Treatment of arterial and venous thromboses
Treatment of arterial and venous thromboses in PV and ET patients should not differ from that recommended in the general population. 81 As recommended in the general population, unfractionated or low-molecular weight heparins are used whenever a rapid anticoagulation is needed, whereas oral anticoagulants are the treatment of choice beyond the acute phase in most patients. Low-molecular weight heparins, in comparison with unfractionated heparin, have a more predictable anticoagulant activity as a variable resistance to unfractionated heparin may arise from increased heparin clearance, elevations in fibrinogen or factor VIII levels and elevations in heparin-binding proteins in plasma. Among these proteins, one has to consider the function of platelet factor 4, which is likely to be more abundantly released in patients with thrombocytosis and/or increased platelet activation. 82 This supports the preferential use of low-molecular weight heparins in MPN subjects. Main indications for the use of heparins are acute coronary syndromes, acute treatment of VTE and prevention of post-operative VTE.
Finally, vitamin K antagonists are used for preventing systemic thromboembolism in patients with chronic atrial fibrillation and heart valve prostheses and for secondary prophylaxis in patients with VTE. In the last setting, the optimal treatment duration is uncertain due to the lack of clinical studies addressing this issue in myeloproliferative disorders. We suggest taking into consideration the type of treatment of the disease as well as the site of thrombosis. Deep vein thrombosis of lower limbs in patients with unrecognized disease or in subjects not receiving chemotherapy can be treated by cytoreduction and a shortterm anticoagulation (3 months) followed by low-dose aspirin, whereas VTE in patients receiving chemotherapy and aspirin may require a longer anticoagulation. Thromboses at unusual sites, such as splanchnic vein and cerebral vein thromboses, are not rare in PV and ET subjects. Early diagnosis of these life-threatening diseases and their treatment are challenging and should be made in specialized centres. Treatment duration in these cases is still controversial and often decided by following the re-canalization of the affected vessel.
The role of JAK2 mutation
Recently, the presence of the acquired gain-of-function V617F mutation in the tyrosine kinase JAK-2 gene has been demonstrated in PMN and platelets of patients with MPN. 7, 8 The majority of patients with MPN carry the identical JAK2 mutation, and using more sensitive methodologies, the frequency of JAK2 mutation is close to 95% in PV and to 50% in ET. 7, 8, 83 At the present time, the impact of the presence of either JAK2 V617F or its allele burden on the prognosis of PV and ET remains uncertain, given the inconsistent observations of various studies. 84 Essential thrombocythaemia patients expressing JAK2 mutation appear to have a 'PV-like' phenotype and also seem to have, compared with the JAK2-negative subjects, an increased incidence of venous thrombosis. 22 The association of the JAK2 mutation with thrombosis at atypical sites is particularly interesting.
In fact, up to 58% of patients with idiopathic (non-cirrhotic) Budd-Chiari syndrome may have this mutation in the absence of overt clinical or haematologic features of an MPN. The mutation has also been identified in a substantial but variable proportion (18-35%) of patients with portal vein or mesenteric vein thrombosis. 85, 86 In this setting, JAK2V617F represents a sensitive marker for 'latent' or 'occult' MPN with a subset of patients subsequently developing clinically overt MPN.
Data recently published in abdominal 87, 88 and cerebral vein thrombosis 89 raise the possibility that the JAK2 mutation might be associated with thrombosis independently of the presence of an MPN.
Certainly, as proposed by Kiladjian et al., 90 the search of JAK2 mutation has become essential in the work-up of patients with splanchnic vein thromboses. On the other hand, the JAK2 mutation, in the absence of an overt MPN, is infrequently detected in patients with thrombosis outside the splanchnic district. 91 As clinical data indicate an association of the JAK2 mutation with thrombosis, it is of interest to understand whether the mutation status may specifically affect the haemostatic system.
It has been reported that the mutation is associated with an increased expression of platelet surface P-selectin and PMN surface-activation markers. 92 A recent study by Falanga et al. 93 investigated the expression of procoagulant, adhesive and inflammatory molecules by platelets and PMN of ET patients, about half of whom expressed the JAK2 mutation. The results show that platelet surface TF (but not P-selectin, CD41 and CD42b) is significantly more elevated in the JAK2 carriers compared with wild-type subjects. The
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Thrombosis in myeloproliferative disorders R Landolfi et al 2025 experiments were conducted in whole blood; therefore, platelets might have either acquired TF from contact with leukocytes or might have released TF from their intracellular stores. 94 These results differ from those of Arellano-Rodrigo et al., 92 and this discrepancy may have several explanations, including the very different patient populations enrolled in the two studies. Compared with the wild-type and control groups, JAK2 V617F mutation carriers also had increased levels of PMN/platelet aggregates. 93 The evidence that both platelets and PMNs from JAK2 mutation carriers expressed increased activation features is in good agreement with the findings of increased mixed-cell aggregate formation in ET patients carrying the JAK2 V617F mutation. It is interesting to note that interaction between platelets and leukocytes favours the cellular activation, metabolic changes and transfer of TF-bearing microparticles between the two cell types. 95, 96 We found an increased TF content in platelets from ET subjects carrying the JAK2 mutation, who also had increased circulating mixed-cell aggregates. 93 Among hypercoagulability parameters, only TM plasma levels were increased in mutation carriers compared with the wildtype ET patients. Likely, the greater PMN activation occurring in JAK2 mutation carriers could render ET patients more susceptible to vascular damage.
Concluding remarks
The haemostatic changes responsible for the increased vascular risk of MPN subjects are still largely elusive. The effect of these changes is potentiated by individual factors so that in subjects with predisposing factors the development of the haematological disorder can make the vascular risk reaching a critical value. This can explain both the tendency of vascular events to cluster around the time of diagnosis and the marked effect of age on thrombotic risk. Many features, however, still escape rational explanations. These include the rather selective occurrence of hepatic vein thrombosis in young female subjects, the differential efficacy of HU in the prevention of arterial and venous events and the surprising efficacy of aspirin in the primary and secondary prevention of venous thromboses. Altogether these observations raise the issue of different types of thrombophilia and of different mechanisms being more prevalent in each case. In this view, research priorities seem to be the function of leukocyte activation in arterial thrombosis and mechanisms linking JAK2 mutation with venous thromboses both at typical and atypical sites. Other research avenues, although potentially interesting, appear to offer less promises to future intervention strategies.
